CTI BioPharma Cash Flow - Annual (NASDAQ:CTIC)

Add to My Stocks
$1.88 $0.02 (1.08%) CTIC stock closing price Sep 18, 2018 (Closing)

The CTI BioPharma cash flow statement is one of the three reports that the company generates every quarter. While its important to look at the CTI BioPharma debt position, the cash flow statement becomes equally important because public companies use accrual accounting. For example, if a company sells a product which gets counted as CTI BioPharma revenue but does not convert to cash because it does not receive payment in the same quarter, it affects the cash position for that period. CTI BioPharma saw a cash impact of $42.66M from the issuance of CTIC shares. The cash flow statement helps in the CTI BioPharma stock analysis by providing more information for evaluating changes in assets, liabilities and equities. CTIC decrease in investments stood at a value of $-0.03M for the latest year 2017.

View details of CTI BioPharma cash flows for latest & last 10 financial years
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Net Income Cash Flow
-40.83M-52.95M-120.76M-94.22M-43.55M-101.68M-62.36M-82.64M-95.39M-180.02M
Depreciation Depletion Amortization Cash-Flow---1.1M1.57M2.34M2.41M1.84M1.77M5.22M
Net Increase (Decrease) in Assets Liabilities-6.17M-8.57M7.45M9.68M-3.79M2.91M-3.85M-5.03M-6.9M78.21M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net6.99M-15.98M17.11M43.89M9.94M33.64M3.34M22.7M12.34M16.37M
Net Cash from (used by) Operating Activities
-39.29M-76.68M-95.2M-39.55M-35.83M-62.77M-60.45M-63.12M-88.18M-80.2M
Increase (Decrease) in Prop Plant And Equipment-0.04M-0.13M-0.07M-0.33M-1.53M-2.93M-2.67M-1.92M-0.59M-1.9M
Acquisition Disposition of Subsidiaires------17.76M--6.84M6.21M
Increase (Decrease) in Investments--------0.35M15.58M-
Other Cash Inflow (Outflow) from Investment Activities----0.2M------
Net Cash from (used by) Investment Activities
-0.03M-0.13M-0.07M-0.54M-1.53M-20.7M-2.67M-2.27M21.84M4.4M
Issuance (Purchase) of Equity Shares42.66M-0.31M114.37M32.59M44.71M87.43M108.59M89.16M114.42M5.08M
Issuance (Repayment) of Debt Securities-3.57M-5.45M6.16M3.43M14.5M--21.16M-38.51M-10.11M174.14M
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions---------3.11M-18.85M
Other Cash from (used by) Financing Activities-0.11M-1.6M31.48M--0.24M-0.21M-0.42M-0.92M-6.42M-86.63M
Net Cash from (used by) Financing Activities
38.97M-7.36M152.01M36.02M58.97M87.21M87M49.72M94.77M73.72M
Effect of Exchange Rate Changes on Cash-0.42M--3.35M-0.4M-0.35M---0.69M-3.65M
Net Change in Cash & Cash Equivalents
-0.78M-84.18M57.24M-0.7M21.2M3.38M24.4M-15.16M27.73M-5.72M
Cash & Equivalents at Beginning of Year44M128.18M70.93M71.63M50.43M47.05M22.64M37.81M10.07M15.79M
Cash & Equivalents at Year End43.21M44M128.18M70.93M71.63M50.43M47.05M22.64M37.81M10.07M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

CTI BioPharma stock price history provides insight into historical stock price fluctuations, and CTI BioPharma stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • Net Change in Cash and Cash Equivalents: A positive net change in cash and cash equivalents shows that CTI BioPharma is able to meet its expenditure and grow cash at hand which demonstrates the financial strength of the company's balance sheet. Also see - CTI BioPharma stock price movement.
  • The cash generated from the core business or operations was a negative at $-39.29M for CTI BioPharma in the latest 2017. For an internet company, this would include all those activities which are involved in eventually selling advertisement space on its website or any online service.
  • Growth companies, typically most tech companies; spend heavily on investing activities and this figure stood at $-0.03M for CTIC stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $38.97M for CTI BioPharma. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Key Financial Ratios For CTI BioPharma Cash Flow